Cornerstone Capital Inc. increased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.9% during the 3rd quarter, Holdings Channel reports. The fund owned 66,171 shares of the medical research company’s stock after acquiring an additional 2,455 shares during the quarter. Amgen comprises approximately 2.1% of Cornerstone Capital Inc.’s portfolio, making the stock its 25th biggest holding. Cornerstone Capital Inc.’s holdings in Amgen were worth $13,717,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in AMGN. FMR LLC boosted its position in shares of Amgen by 4.4% during the 3rd quarter. FMR LLC now owns 35,823,268 shares of the medical research company’s stock valued at $7,425,805,000 after acquiring an additional 1,505,266 shares during the last quarter. Natixis boosted its position in shares of Amgen by 2,612.1% during the 2nd quarter. Natixis now owns 529,816 shares of the medical research company’s stock valued at $97,799,000 after acquiring an additional 510,281 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its position in shares of Amgen by 54.8% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 1,075,050 shares of the medical research company’s stock valued at $222,847,000 after acquiring an additional 380,562 shares during the last quarter. O Shaughnessy Asset Management LLC boosted its position in shares of Amgen by 404.6% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 456,500 shares of the medical research company’s stock valued at $94,333,000 after acquiring an additional 366,027 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Amgen by 17.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock valued at $436,551,000 after acquiring an additional 343,690 shares during the last quarter. 76.94% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ AMGN opened at $191.44 on Friday. Amgen, Inc. has a 12 month low of $163.31 and a 12 month high of $210.19. The company has a debt-to-equity ratio of 2.05, a quick ratio of 2.84 and a current ratio of 3.08. The stock has a market capitalization of $126.81 billion, a price-to-earnings ratio of 15.22, a P/E/G ratio of 2.07 and a beta of 1.41.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, beating the Zacks’ consensus estimate of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company had revenue of $5.90 billion for the quarter, compared to analysts’ expectations of $5.78 billion. During the same quarter in the prior year, the company posted $3.27 earnings per share. Amgen’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, analysts predict that Amgen, Inc. will post 14.24 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be given a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 3.03%. This is a boost from Amgen’s previous quarterly dividend of $1.32. Amgen’s dividend payout ratio is presently 41.97%.

Several brokerages have recently weighed in on AMGN. Royal Bank of Canada reissued a “neutral” rating and set a $193.00 price target on shares of Amgen in a research report on Monday, September 10th. Jefferies Financial Group reissued a “buy” rating and set a $220.00 price target on shares of Amgen in a research report on Monday, October 1st. Oppenheimer reissued a “buy” rating and set a $224.00 price target on shares of Amgen in a research report on Tuesday, August 28th. Wells Fargo & Co reissued a “neutral” rating and set a $197.00 price target on shares of Amgen in a research report on Wednesday, August 29th. Finally, Citigroup boosted their price target on shares of Amgen from $200.00 to $204.00 and gave the company a “neutral” rating in a research report on Thursday, November 1st. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Amgen presently has a consensus rating of “Hold” and a consensus price target of $205.68.

In other Amgen news, SVP Cynthia M. Patton sold 1,777 shares of the company’s stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $202.88, for a total value of $360,517.76. Following the transaction, the senior vice president now owns 23,090 shares of the company’s stock, valued at $4,684,499.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cornerstone Capital Inc. Purchases 2,455 Shares of Amgen, Inc. (AMGN)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/cornerstone-capital-inc-purchases-2455-shares-of-amgen-inc-amgn/2669664.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Read More: What is Depreciation?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.